| 1 | dynamic neuroscreening device dnd | | | | | | | 2 | 0.93% |
| 2 | to take full advantage | | | | | | | 1 | 0.47% |
| 3 | of the major causes | | | | | | | 1 | 0.47% |
| 4 | excellence awards mdea medical | | | | | | | 1 | 0.47% |
| 5 | awards mdea medical necessity | | | | | | | 1 | 0.47% |
| 6 | mdea medical necessity peripheral | | | | | | | 1 | 0.47% |
| 7 | medical necessity peripheral neuropathy | | | | | | | 1 | 0.47% |
| 8 | necessity peripheral neuropathy is | | | | | | | 1 | 0.47% |
| 9 | peripheral neuropathy is one | | | | | | | 1 | 0.47% |
| 10 | the major causes of | | | | | | | 1 | 0.47% |
| 11 | in 2016 worldwide medical | | | | | | | 1 | 0.47% |
| 12 | major causes of sensation | | | | | | | 1 | 0.47% |
| 13 | causes of sensation loss | | | | | | | 1 | 0.47% |
| 14 | of sensation loss and | | | | | | | 1 | 0.47% |
| 15 | sensation loss and significantly | | | | | | | 1 | 0.47% |
| 16 | loss and significantly increases | | | | | | | 1 | 0.47% |
| 17 | and significantly increases risk | | | | | | | 1 | 0.47% |
| 18 | of feet ulceration with | | | | | | | 1 | 0.47% |
| 19 | feet ulceration with potential | | | | | | | 1 | 0.47% |
| 20 | 2016 worldwide medical design | | | | | | | 1 | 0.47% |
| 21 | winner in 2016 worldwide | | | | | | | 1 | 0.47% |
| 22 | with potential limb loss | | | | | | | 1 | 0.47% |
| 23 | designed noninvasive screening device | | | | | | | 1 | 0.47% |
| 24 | screening for peripheral neuropathy | | | | | | | 1 | 0.47% |
| 25 | for peripheral neuropathy simple | | | | | | | 1 | 0.47% |
| 26 | peripheral neuropathy simple objective | | | | | | | 1 | 0.47% |
| 27 | neuropathy simple objective grading | | | | | | | 1 | 0.47% |
| 28 | temperature discrimination vibration discrimination | | | | | | | 1 | 0.47% |
| 29 | discrimination vibration discrimination physician | | | | | | | 1 | 0.47% |
| 30 | conceived and designed noninvasive | | | | | | | 1 | 0.47% |
| 31 | and designed noninvasive screening | | | | | | | 1 | 0.47% |
| 32 | noninvasive screening device earliest | | | | | | | 1 | 0.47% |
| 33 | bronze winner in 2016 | | | | | | | 1 | 0.47% |
| 34 | take full advantage of | | | | | | | 1 | 0.47% |
| 35 | screening of peripheral neuropathy | | | | | | | 1 | 0.47% |
| 36 | of peripheral neuropathy t1dm2d2 | | | | | | | 1 | 0.47% |
| 37 | peripheral neuropathy t1dm2d2 2016 | | | | | | | 1 | 0.47% |
| 38 | neuropathy t1dm2d2 2016 diabetes | | | | | | | 1 | 0.47% |
| 39 | t1dm2d2 2016 diabetes innovation | | | | | | | 1 | 0.47% |
| 40 | challenge finalist bronze winner | | | | | | | 1 | 0.47% |